ImmuCell Co. (NASDAQ:ICCC) Short Interest Update

ImmuCell Co. (NASDAQ:ICCC) was the target of a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 13,200 shares, a decrease of 22.8% from the February 28th total of 17,100 shares. Currently, 0.2% of the shares of the stock are sold short. Based on an average trading volume of 8,000 shares, the short-interest ratio is presently 1.7 days.

Hedge Funds Weigh In On ImmuCell

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Mesirow Financial Investment Management Inc. raised its stake in shares of ImmuCell by 100.0% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 24,356 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 12,178 shares during the last quarter. Citadel Advisors LLC purchased a new stake in ImmuCell in the 4th quarter valued at approximately $149,000. Northern Trust Corp lifted its holdings in ImmuCell by 51.0% in the 4th quarter. Northern Trust Corp now owns 44,374 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 14,982 shares in the last quarter. Geode Capital Management LLC raised its holdings in ImmuCell by 13.9% in the 4th quarter. Geode Capital Management LLC now owns 64,538 shares of the biotechnology company’s stock valued at $332,000 after acquiring an additional 7,878 shares during the last quarter. Finally, Dauntless Investment Group LLC acquired a new position in ImmuCell in the fourth quarter valued at $676,000. 13.47% of the stock is owned by institutional investors and hedge funds.

ImmuCell Stock Performance

Shares of ImmuCell stock remained flat at $5.01 on Monday. The company had a trading volume of 178 shares, compared to its average volume of 18,980. The firm has a market cap of $44.65 million, a P/E ratio of -10.02 and a beta of 0.62. The firm’s 50-day moving average is $5.12 and its two-hundred day moving average is $4.47. The company has a quick ratio of 1.44, a current ratio of 3.11 and a debt-to-equity ratio of 0.36. ImmuCell has a 1 year low of $3.34 and a 1 year high of $5.82.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings data on Tuesday, February 25th. The biotechnology company reported $0.06 earnings per share for the quarter. ImmuCell had a negative return on equity of 15.32% and a negative net margin of 15.99%. The company had revenue of $7.75 million for the quarter.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.